S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
LCTX · Lineage Cell Therapeutics, Inc.
NYSE MKT LLC - BOATS Real Time Price • USD
$0.96
-0.03
(-2.94%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.96
$0.94
$0.98
52-WEEK RANGE
$0.96
$0.88
$2.09
What's happening
- LCTX is down 2.94% today, trading at $0.96. — Live quote
- Volume today (64,693) is well below its 3-month average of 1,425,390. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.01 actual vs. $-0.03 estimated (+134.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LCTX
-41.76%
vs S&P 500
-54.54%
1-YEAR RETURN
LCTX
-40.70%
vs S&P 500
-55.26%
6-MONTH RETURN
LCTX
-40.70%
3-MONTH RETURN
LCTX
-14.68%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.01
Est. $-0.03
BEAT +134.6%
2026-04-26 (Q1 2026)
$-0.03
Est. $-0.02
MISS -47.1%
2026-01-26 (Q4 2025)
$0.00
Est. $-0.05
BEAT +100.0%
2025-10-26 (Q3 2025)
$-0.13
Est. $-0.03
MISS -396.2%
Valuation Measures & Ratios
Enterprise Value4$203.2M
Forward P/E5—
PEG Ratio6-5.35
Price / Sales (TTM1)19.32
Price / Book75.36
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-263.65%
Operating Margin-285.11%
Return on Equity (ROE8)-71.14%
Return on Assets (ROA9)-30.87%
Avg Volume (3M)1,425,390
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | $251.8M | $388.3M | $213.9M | $93.7M |
| P/E | — | -3.64 | -5.76 | -4.93 | -4.81 |
| Price/Sales | — | 26.03 | 33.11 | 22.63 | 11.52 |
| Price/Book | — | 4.67 | 17.62 | 4.42 | 1.19 |
| EV/Revenue | — | 22.32 | 29.66 | 18.16 | 5.63 |
| ROE | — | -128.44% | -305.89% | -89.69% | -24.64% |
| ROA | — | -63.17% | -75.21% | -47.79% | -17.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short29,093,018
Change from Prior Settlement-1.27%
% of Float—
Days to Cover (Short Ratio)15.75
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -58.4% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -263.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -40.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LCTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $3.7M | $2.8M | $1.5M | $3.8M | $1.4M | $1.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.9M | -$7.6M | -$3.8M | -$19.8M | -$6.5M | -$3.8M | -$5.9M | -$6.7M |
| Net income | $1.5M | -$4.8M | -$29.8M | -$30.5M | -$4.1M | -$3.0M | -$5.8M | -$6.5M |
| EPS (diluted) | $-0.03 | $-0.03 | $-0.13 | $-0.13 | $-0.02 | $-0.02 | $-0.03 | $-0.04 |
| EPS (basic) | $0.01 | $-0.02 | $-0.13 | $-0.13 | $-0.02 | $-0.02 | $-0.03 | $-0.04 |
| Operating margin | -$835 | -$440 | -$103 | -$715 | -$433 | -$102 | -$417 | -$461 |
| Net margin | $139 | -$279 | -$809 | -$1.1K | -$276 | -$80 | -$409 | -$453 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $106.2M | $109.5M | $112.6M | $89.6M | $90.8M | $111.8M | $113.2M | $96.6M |
| Total liabilities | $46.4M | $56.8M | $69.2M | $68.8M | $43.7M | $34.1M | $36.2M | $31.8M |
| Stockholders' equity | $60.9M | $53.9M | $44.5M | $22.0M | $48.4M | $79.0M | $78.4M | $66.2M |
| Total current assets | $53.0M | $56.2M | $59.2M | $42.3M | $43.8M | $50.0M | $51.0M | $34.4M |
| Total current liabilities | $8.0M | $8.1M | $11.4M | $9.4M | $10.8M | $13.1M | $14.0M | $13.9M |
| Cash & equivalents | $37.4M | $35.9M | $40.8M | $40.5M | $42.3M | $47.9M | $45.8M | $27.8M |
| Marketable securities (current) | $13.5M | $17.4M | $15.0M | $23.0K | $17.0K | $19.0K | $2.0M | $5.0M |
| Accounts receivable | $790.0K | $806.0K | $891.0K | $127.0K | $256.0K | $213.0K | $638.0K | $405.0K |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.5M | $2.5M | $2.6M | $2.2M | $2.3M | $2.1M | $2.3M | $2.0M |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M |
| Intangible assets | $31.7M | $31.7M | $31.7M | $31.7M | $31.7M | $46.5M | $46.5M | $46.5M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.5M | $1.6M | $2.3M | $1.5M | $1.5M | $2.0M | $1.2M | $1.6M |
| Accrued liabilities | $1.0M | $1.2M | $1.1M | $486.0K | $793.0K | $902.0K | $1.2M | $384.0K |
| Deferred revenue (current) | $1.7M | $1.7M | $3.3M | $3.8M | $5.3M | $6.9M | $7.4M | $8.2M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $535.7M | $529.7M | $515.5M | $494.2M | $490.6M | $489.3M | $484.7M | $469.3M |
| Retained earnings | -$470.3M | -$471.8M | -$467.0M | -$467.8M | -$438.1M | -$407.6M | -$403.5M | -$400.2M |
| Accumulated other comprehensive income (loss) | -$4.5M | -$4.0M | -$3.9M | -$4.3M | -$4.1M | -$2.7M | -$2.9M | -$2.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$8.1M | -$4.9M | -$3.6M | -$5.5M | -$4.9M | -$6.3M | -$5.8M |
| Investing cash flow | $4.0M | -$2.3M | -$15.3M | -$12.0K | -$14.0K | $1.9M | $2.6M | $3.9M |
| Financing cash flow | $4.5M | $5.6M | $20.4M | $1.8M | -$307.0K | $5.0M | $21.7M | -$3.0K |
| Free cash flow | -$7.4M | -$8.1M | -$5.3M | -$3.6M | -$5.6M | -$5.0M | -$6.7M | -$5.9M |
| Capital expenditures | $108.0K | $55.0K | $399.0K | $12.0K | $14.0K | $97.0K | $365.0K | $112.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.6M | $1.2M | $1.1M | $1.2M | $1.2M | $1.2M | $1.3M | $1.3M |
| Deferred income taxes | $0 | $0 | -$5.3M | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | -$19.0K | -$154.0K | $827.0K | -$130.0K | $43.0K | -$424.0K | $233.0K | $169.0K |
| Change in inventory | — | — | — | — | — | — | — | — |
| Purchases of investments | $10.4M | $8.2M | $14.9M | $0 | $0 | $0 | $0 | $0 |
| Other investing activities | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $40.0K | $1.0K | $0 | $0 | $15.0K | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M |
| Gross profit | — | — | $8.3M | $14.0M | $2.9M |
| Operating income | -$36.6M | -$21.5M | -$24.7M | -$22.5M | -$49.2M |
| Net income | -$63.5M | -$18.6M | -$21.5M | -$26.3M | -$43.0M |
| EPS (diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | — |
| EPS (basic) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 |
| Operating margin | -$252 | -$226 | -$277 | -$153 | -$1.1K |
| Net margin | -$436 | -$196 | -$240 | -$179 | -$991 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M |
| Stockholders' equity | $44.5M | $78.4M | $63.4M | $73.3M | $92.2M |
| Total current assets | $59.2M | $51.0M | $38.4M | $60.0M | $111.5M |
| Total current liabilities | $11.4M | $14.0M | $18.0M | $19.0M | $47.1M |
| Cash & equivalents | $40.8M | $45.8M | $35.4M | $11.4M | $55.7M |
| Marketable securities (current) | $15.0M | $2.0M | $50.0K | $46.5M | $2.6M |
| Accounts receivable | $891.0K | $638.0K | $745.0K | $297.0K | — |
| Inventory | — | — | — | — | — |
| Property, plant & equipment | $2.6M | $2.3M | $2.2M | $5.7M | $4.9M |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M |
| Intangible assets | $31.7M | $46.5M | $46.6M | $46.7M | $46.8M |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $2.3M | $1.2M | $2.0M | $2.4M | $3.5M |
| Accrued liabilities | $1.1M | $1.2M | $1.1M | $3.8M | $22.1M |
| Deferred revenue (current) | $3.3M | $7.4M | $10.8M | $9.4M | $18.1M |
| Other non-current liabilities | — | — | $0 | $2.0K | $30.0K |
| Common stock & paid-in capital | $515.5M | $484.7M | $451.3M | $440.3M | $434.5M |
| Retained earnings | -$467.0M | -$403.5M | -$384.9M | -$363.4M | -$337.1M |
| Accumulated other comprehensive income (loss) | -$3.9M | -$2.9M | -$3.1M | -$3.6M | -$5.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.9M | -$23.1M | -$28.6M | $1.1M | -$23.6M |
| Investing cash flow | -$13.5M | -$2.3M | $46.4M | -$46.2M | $9.7M |
| Financing cash flow | $26.9M | $35.9M | $6.4M | $1.6M | $36.9M |
| Free cash flow | -$19.4M | -$23.7M | -$29.2M | $646.0K | -$23.9M |
| Capital expenditures | $522.0K | $565.0K | $674.0K | $413.0K | $340.0K |
| Depreciation & amortization | — | — | — | $582.0K | $663.0K |
| Share-based compensation | $4.8M | $5.1M | $4.6M | $4.3M | $3.5M |
| Deferred income taxes | -$5.3M | $0 | -$1.8M | $0 | — |
| Change in accounts receivable | $316.0K | -$106.0K | $446.0K | -$50.3M | $857.0K |
| Change in inventory | — | — | — | — | — |
| Purchases of investments | $14.9M | $8.8M | $16.4M | $53.4M | — |
| Tax withholding on stock comp | $16.0K | $23.0K | $37.0K | $17.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LCTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:59 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-09 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-03-12 | 4 | 2026-03-12 | View on SEC.gov → |
Recent news
Headlines about LCTX (Lineage Cell Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
(AMEX: LCTX) Share Price, LCTX Stock News, LCTX Share Price & Updates
kalkine.ca · 2026-10-15 -
Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
Benzinga · 2026-10-12 -
3 Small Cap Stocks With Strong Revenue Growth And Low Debt
Yahoo Finance · 2026-09-16 -
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Yahoo Finance · 2026-09-08 -
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk
Seeking Alpha · 2026-09-01 -
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-14 -
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-09 -
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 2026-08-07
No headlines in this category right now — try “All”.